The popularity of abdominally based free flap breast reconstruction has grown tremendously over the past decade. However, controversy persists regarding the safety of performing these operations in individuals with a prior history of abdominal surgery.
PURPOSE:
The impact of neoadjuvant and adjuvant chemotherapy on outcomes in nipple-sparing mastectomy (NSM) have not yet been established.
METHODS:
Patients undergoing NSM from 2006 to June 2015 were identified. Results were analyzed for reconstructions receiving neoadjuvant or adjuvant chemotherapy.
RESULTS:
Of 840 NSMs, 28 received neoadjuvant chemotherapy while 93 received adjuvant chemotherapy.
NSMs with neoadjuvant chemotherapy were significantly more likely to have implant explantation (p=0.0015) and complete nipple necrosis (p=0.0004) compared to those with no chemotherapy. Compared to NSMs with no chemotherapy, those with adjuvant chemotherapy were significantly more likely to have hematoma formation (p=0.0021). Those with neoadjuvant chemotherapy were significantly more likely to have explantation (p=0.0239) and complete nipple necrosis (p=0.0021) compared to those with adjuvant chemotherapy.
NSMs with both neoadjuvant and adjuvant chemotherapy were significantly more likely to have complete nipple necrosis compared to those with neoadjuvant chemotherapy only and adjuvant chemotherapy only (p<0.0001). No differences were observed in NSMs with neoadjuvant chemotherapy and adjuvant radiation compared to NSMs with neoadjuvant chemotherapy alone.
CONCLUSIONS:
NSM is safe to perform in the setting of neoadjuvant and adjuvant chemotherapy. However, neoadjuvant chemotherapy appears to increase complications; a synergistic effect between neoadjuvant and adjuvant chemotherapy likely yields overall greatest risk. 
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BILATERAL BREAST REDUCTION OUTCOMES IN PATIENTS WITH AUTOIMMUNE CONNECTIVE TISSUE DISEASE
Gustavo
University of Miami Leonard M. Miller School of Medicine, Miami, FL, USA.
PURPOSE: Autoimmune connective tissue diseases (CTDs) are associated with a wide spectrum of soft tissue and systemic manifestations that may significantly impact outcomes in elective breast surgery. Purpose of this study was to evaluate whether CTDs are associated with an increased rate of complications following bilateral breast reductions. PRS Global Open • 2017 METHOD: Nationwide Inpatient Sample (2006-2011) was queried to identify bilateral breast reduction cases. Patients with rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, Raynaud's syndrome, psoriatic arthritis, or scleroderma were identified. Demographic factors, comorbidities, and postoperative complications were compared to patients without CTD using student t-test, chi-square, and risk-adjusted multivariate logistic regression.
RESULTS:
A total of 22,653 bilateral breast reductions were performed during study period. Of these, 428 (1.9%) were performed in patients with CTD. Patients with CTD were older (50.5 vs 42.5 years, respectively) and had higher rates of co-morbidities compared to non-CTD patients (p<0.01). Postoperatively, patients with CTD experienced higher rates of wound infections (1.2% vs 0.2%, p<0.01), venous thromboembolism (2.3% vs 0.2%, p<0.01), and major medical complications (4.4% vs 1.8%, p<0.01) compared to non-CTD patients, respectively. On multivariate logistic regression analyses, CTDs were independently associated with increased risk of wound infection (OR 3.6, 95% CI 1.3-10.5), venous thromboembolism (OR 11.7, 95% CI 5.6-24.7), and other major medical complications (OR 1.8, 95% CI 1.1-3.0).
CONCLUSION:
Patients with CTD are at significantly increased risk for complications following elective bilateral breast reduction. Such high risk patients require careful patient selection and strategies to minimize risk of serious postoperative complications including venous thromboembolism.
COMPREHENSIVE 13-YEAR REVIEW OF IMPLANT-BASED BREAST RECONSTRUCTION: IS TOTAL MUSCLE COVERAGE OR ALLODERM HUMAN DERMAL MATRIX BETTER?
Simon Ivey, M.D. 
RESULTS:
A total of 277 patients underwent placement of 466 breast tissue expanders. Although the total overall complication rate was not significantly different between the Alloderm and Total Muscle (TM) groups (31.4% vs. 21.5%, p>0.05), the rate of major complications was significantly higher with Alloderm (26.7% vs. 11.7%, p<.004). The mean initial fill volume was significantly lower in TM compared to Alloderm group (54 ± 47 vs. 167 ± 139, p=0.00003) resulting in a higher number of expansions in patients with total muscle coverage (7.7 vs. 6.1, p=0.00076). However, there was no difference in time to exchange for permanent implant (160.4 vs. 165.8 days, p>0.05). There is also an increased rate of revisions with Alloderm after average follow-up of 55.7 months (10.7% vs. 4.4%, p<0.01). Use of Alloderm added a mean cost of $2,217 for each breast.
CONCLUSION:
Although the use of Alloderm allows increased initial fill volumes and fewer total expansions, this study shows an increased risk of major complications as well as considerable added cost without the touted benefits of decreasing revisions or time to expander exchange. Total muscle coverage remains an excellent option for providing quality breast reconstruction without increased complications.
